Reading iventory : for the classroom / by 449570 Flynt, E. Sutton, Cooter, Robert B.

Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma by Amatangelo, M, Flynt, E, Stong, N, Ray, P, Van Oekelen, O, Wang, M, Ortiz, M, Maciag, P, Peluso, T, Parekh, S, van de Donk, NWCJ, Lonial, S, Thakurta, A

Loss of COP9 signalosome gene-containing 2q region is associated with lenalidomide and pomalidomide resistance in myeloma patients by Gooding, S, Ansari-Pour, N, Kazeroun, MH, Karagoz, K, Salazar, MA, Fitzsimons, E, Estevez, MO, Towfic, F, Flynt, E, Pierceall, WE, Yong, K, Vyas, P, Thakurta, A

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma by Gooding, S, Ansari-Pour, N, Towfic, F, Ortiz Estévez, M, Chamberlain, PP, Tsai, K-T, Flynt, E, Hirst, M, Rozelle, D, Dhiman, P, Neri, P, Ramasamy, K, Bahlis, N, Vyas, P, Thakurta, A

Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma by Van Oekelen, O, Amatangelo, M, Guo, M, Upadhyaya, B, Cribbs, AP, Kelly, G, Patel, M, Kim-Schulze, S, Flynt, E, Lagana, A, Gooding, S, Merad, M, Jagganath, S, Pierceall, WE, Oppermann, U, Thakurta, A, Parekh, S

Loss Of COP9-signalosome genes Aa 2q37 is associated with IMiD agent resistance in multiple myeloma by Gooding, S, Ansari-Pour, N, Kazeroun, MH, Karagoz, K, Polonskaia, A, Angulo Salazar, M, Fitzsimons, E, Sirinukunwattana, K, Chavda, SJ, Ortiz Estevez, M, Towfic, F, Flynt, E, Pierceall, W, Royston, D, Yong, KL, Ramasamy, K, Vyas, P, Thakurta, A